Fevertree Drinks (FEVR) Trading Update summary
Event summary combining transcript, slides, and related documents.
Trading Update summary
9 Jun, 2025Trading performance and outlook
Trading remains in line with expectations, with strong US momentum following the Molson Coors partnership and consensus for low revenue growth and ~12% adjusted EBITDA margin for FY25.
US market growth is supported by the transition to Molson Coors' distribution, with both companies aligned on significant future opportunities.
UK leadership is maintained across both on-trade and off-trade channels, leveraging brand strength and portfolio diversity to capture growth in alcoholic and non-alcoholic segments.
European markets show good momentum, especially in the Netherlands, though Germany remains muted; Ginger Beer drives broader consumption occasions.
Local production in Australia has commenced, supporting market share growth in the Rest of World region.
Strategic partnership and operational updates
The Molson Coors partnership is progressing well, with the transition of US distribution on track and expected to benefit from Molson Coors' scale and supply chain.
A new 10% US tariff on UK imports will be shared equally with Molson Coors, with mitigation strategies in place, including on-shoring US production and a profit guarantee mechanism.
Charles Gibb steps down as US CEO, succeeded by Judd Hausner, who brings extensive experience in the US beverage sector.
Capital allocation and share buyback
Share buyback program of £71 million initiated in February 2025, extended by £20 million, with £42.5 million returned as of 30 May 2025; remainder to be returned over the year.
Strong balance sheet and improved cash flow prospects support continued investment in operations and marketing, with surplus cash to be returned to shareholders.
M&A opportunities are being considered to further strategic delivery, while maintaining an asset-light business model.
Latest events from Fevertree Drinks
- FY25 revenue and EBITDA to surpass expectations, with robust US and global growth.FEVR
Trading update29 Jan 2026 - 79% EBITDA growth and 520bps margin gain in H1, with strong US and global share gains.FEVR
H1 202420 Jan 2026 - Molson Coors takes 8.5% stake, US operations, and guarantees royalties for accelerated growth.FEVR
Partnership9 Jan 2026 - Robust FY24 growth, margin recovery, and U.S. partnership drive future gains.FEVR
H2 202424 Dec 2025 - US partnership, diversification, and strong cash drive growth; outlook and buybacks positive.FEVR
H1 202512 Sep 2025 - Fever-Tree delivers market share gains and reaffirms full year outlook with global growth.FEVR
Trading Update13 Jun 2025